Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications
20 sept. 2021 08h00 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development...
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
30 août 2021 08h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b clinical...
180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement
24 août 2021 08h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development...
180 Life Sciences Corp. Announces $15.0 Million Private Placement
19 août 2021 09h00 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of...
Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021
02 août 2021 08h00 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development...
180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
29 juil. 2021 08h00 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development...
180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue
28 juil. 2021 08h15 HE
|
180 Life Sciences Corp.
MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development...
180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
20 juil. 2021 08h00 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development...
180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)
12 juil. 2021 09h51 HE
|
180 Life Sciences Corp.
MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development...
180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal
07 juil. 2021 08h00 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development...